Literature DB >> 30993941

Response: Projection of Diabetes Prevalence in Korean Adults for the Year 2030 Using Risk Factors Identified from National Data (Diabetes Metab J 2019;43:90-6).

Inkyung Baik1.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 30993941      PMCID: PMC6470096          DOI: 10.4093/dmj.2019.0060

Source DB:  PubMed          Journal:  Diabetes Metab J        ISSN: 2233-6079            Impact factor:   5.376


× No keyword cloud information.
I would like to express my sincere thanks for Dr. Koo's comments on the recently published article about the projected prevalence of diabetes mellitus (DM) in Korean adults [1]. In this article, the current and future prevalence estimates of DM were calculated among adults aged 30 years or older because this age-range was used in the report of the Korea National Health and Nutrition Examination Survey [2]. Accordingly, it is reasonable that the projected prevalence for the year 2030 presented in the article [1] was relatively higher than an estimate among adults aged 20 to 79 years proposed by the International Diabetes Federation (IDF) [3]. In addition, the method which was used to obtain the IDF's estimates is likely to produce underestimated projections as indicated in an earlier report [4]. If the denominator is changed into the number of adults aged 20 to 79 years, the prevalence of DM at the year 2030 would be 18.9% (13.8% in women and 23.9% in men) using the same method of the article [1]. Furthermore, if the denominator is the number of the total Korean population, the prevalence of DM at the year 2030 would be 14.2% (10.0% in women and 18.3% in men), which is comparable to the prevalence (15.3%) projected in the total United States population [5]. The IDF has also speculated that the projections of DM prevalence for the United States and Republic of Korea at the year 2030 would be similar [3]. Being intrigued by Dr. Koo's suggestion regarding age-group-specific projections, further analysis has been attempted; projected prevalence estimates are 10.6% (7.8% in women and 13.4% in men) for adults aged 20 to 64 years (the younger) and 43.6% (31.7% in women and 55.4% in men) for those aged 65 to 79 years (the older) when considering the population projection at 2030 [6]. Before considering it, however, 9.1% (6.3% in women and 11.9% in men) in the younger and 26.8% (23.1% in women and 30.4% in men) in the older have been estimated. Interpreting these results, I agree with Dr. Koo's speculation regarding an increasing trend in DM prevalence among male adults due to increasing prevalence of risk factors including obesity as well as among male and female elders due to an increasing size of the elderly population. Thus, the suggestion of forecasting age-specific prevalence of DM is quite worthy of being considered.
  4 in total

1.  IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030.

Authors:  David R Whiting; Leonor Guariguata; Clara Weil; Jonathan Shaw
Journal:  Diabetes Res Clin Pract       Date:  2011-11-12       Impact factor: 5.602

2.  The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults.

Authors:  Leonor Guariguata; David Whiting; Clara Weil; Nigel Unwin
Journal:  Diabetes Res Clin Pract       Date:  2011-11-17       Impact factor: 5.602

3.  Projection of Diabetes Prevalence in Korean Adults for the Year 2030 Using Risk Factors Identified from National Data.

Authors:  Inkyung Baik
Journal:  Diabetes Metab J       Date:  2018-10-31       Impact factor: 5.376

4.  Diabetes 2030: Insights from Yesterday, Today, and Future Trends.

Authors:  William R Rowley; Clement Bezold; Yasemin Arikan; Erin Byrne; Shannon Krohe
Journal:  Popul Health Manag       Date:  2016-04-28       Impact factor: 2.459

  4 in total
  1 in total

1.  Machine Learning Based Diabetes Classification and Prediction for Healthcare Applications.

Authors:  Umair Muneer Butt; Sukumar Letchmunan; Mubashir Ali; Fadratul Hafinaz Hassan; Anees Baqir; Hafiz Husnain Raza Sherazi
Journal:  J Healthc Eng       Date:  2021-09-29       Impact factor: 2.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.